Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
MIAMI, Jan. 5, 2011 /PRNewswire/ — The Alpha-1 Foundation announced today that it has awarded two research grants to investigators whose research will contribute to our understanding of the causes and mechanisms that give rise to lung disease. The first grant will investigate how cigarette smoke promotes the onset of emphysema through the destruction of elastic fibers in the lung, and how the alpha(1)-proteinase inhibitor (A1PI) protein protects the elastic fibers from degradation. The second grant will evaluate how the alpha(1)-proteinase inhibitor (A1PI) interacts with lung cells and plasma membranes. A1PI plays an essential role in the lung, limiting the activity of destructive enzymes released by inflammatory cells. In addition, environmental and genetic factors can reduce levels of A1PI, which can then lead to emphysema.
The annual research grants are part of the Alpha-1 Foundation’s ongoing commitment to increase the understanding of alpha-1 antitrypsin deficiency, a genetic disorder in which low levels of the A1PI protein can result in liver damage and emphysema. The 2010 research grants were awarded to Kamal Akhtar, PhD, of the Washington University School of Medicine, St. Louis, MO and Irina Petrache, MD, of Indiana University, Indianapolis, IN.
Akhtar’s team will study how the destructive oxidants in cigarette smoke cause two-fold damage in the lungs by degrading elastic fibers that allow the lungs to stretch and recoil and by damaging A1PI so it does not function correctly. A1PI normally acts in the lungs by inhibiting and neutralizing inflammatory enzymes that can break down elastic fibers.
Petrache’s team will study how A1PI interacts with lung cells, and how defects in the structure of A1PI can affect these functions. Specifically, Petrache will study variations to the alpha-1 protein made by removing its sugar molecules to determine how this change affects the ability of A1PI to enter the cells and interact with their membranes.
These grants were made possible through an unrestricted charitable donation from Talecris Biotherapeutics to the Alpha-1 Foundation.
“Our goal is to further the understanding of emphysema and the environmental and genetic factors that give rise to this chronic disease,” said John Walsh, President and CEO of the Alpha-1 Foundation. “Studying the mechanisms that cause lung disease will ultimately enable the medical community to develop more effective means of prevention and treatment.”
About Alpha(1)-Antitrypsin Deficiency
Alpha(1)-antitrypsin deficiency, also known as AAT deficiency or Alpha-1, is an inherited disorder that causes significant reduction in the naturally occurring protein alpha(1)-proteinase inhibitor. It is most common in the Caucasian population of northern Europe and North America. AAT deficiency is also the most common cause of genetic liver disease in children, and genetic emphysema (shortness of breath) in adults. Individuals suffering from AAT deficiency often develop severe chronic obstructive pulmonary disease (COPD) causing disability and premature death. AAT deficiency is estimated to affect 200,000 people in North America and Europe combined, although greater than 90% remain undiagnosed.
About the Alpha-1 Foundation:
The mission of the Alpha-1 Foundation is to provide the leadership and resources that will result in increased research, improved health, worldwide detection, and a cure for Alpha-1 Antitrypsin Deficiency. For more information, please visit: www.alphaone.org.
About Talecris Biotherapeutics: Inspiration. Dedication. Innovation.
Talecris Biotherapeutics (Nasdaq: TLCR) is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, neurology and hemostasis. (www.talecris.com)
Cautionary statement regarding forward-looking statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, quotations from management in this press release, statements regarding strategic and operation plans, and statements regarding the development or commercialization of therapies. Forward-looking statements are based on current beliefs and expectations and are subject to inherent risks and uncertainties. You are cautioned not to place undue reliance on forward-looking statements. Although Talecris believes that the forward-looking statements contained in this press release are reasonable, there is no assurance that expectations will be fulfilled.
The following factors, among others, could cause actual results to differ materially from those expressed or implied in forward-looking statements: possible U.S. legislation or regulatory action affecting, among other things, the U.S. healthcare system, pharmaceutical pricing and reimbursement, including Medicaid and Medicare; our ability to procure adequate quantities of plasma and other materials which are acceptable for use in our manufacturing processes from our own plasma collection centers or from third-party vendors; our ability to maintain compliance with government regulations and licenses, including those related to plasma collection, production and marketing; our ability to identify growth opportunities for existing products and our ability to identify and develop new product candidates through our research and development activities; and the timing of, and our ability to, obtain and/or maintain regulatory approvals for new product candidates, the rate and degree of market acceptance, and the clinical utility of our products. Additional information about factors that could affect the business and financial results of Talecris is contained in its final Prospectus filed pursuant to Rule 424(b)(1) with the Securities and Exchange Commission on October 1, 2009. Talecris undertakes no duty to update any forward-looking statement.
SOURCE Alpha-1 Foundation